Insider Transactions in Q4 2023 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,541
-4.69%
|
$35,410
$10.0 P/Share
|
|
Dec 19
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,906
-12.63%
|
$109,060
$10.0 P/Share
|
|
Oct 31
2023
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,633
-4.64%
|
$8,165
$5.2 P/Share
|
|
Oct 31
2023
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,232
-7.47%
|
$6,160
$5.2 P/Share
|
|
Oct 31
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,080
-1.23%
|
$5,400
$5.2 P/Share
|
|
Oct 30
2023
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,207
+7.1%
|
-
|
|
Oct 30
2023
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,924
+11.27%
|
-
|
|
Oct 30
2023
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,886
+2.75%
|
-
|